IL122464A - נגזרות של n-פיראזין- פירידינסולפונאמיד, תהליך להכנתן ותערובות רוקחיות המכילות אותן - Google Patents

נגזרות של n-פיראזין- פירידינסולפונאמיד, תהליך להכנתן ותערובות רוקחיות המכילות אותן

Info

Publication number
IL122464A
IL122464A IL12246496A IL12246496A IL122464A IL 122464 A IL122464 A IL 122464A IL 12246496 A IL12246496 A IL 12246496A IL 12246496 A IL12246496 A IL 12246496A IL 122464 A IL122464 A IL 122464A
Authority
IL
Israel
Prior art keywords
alkyl
alkoxy
methoxy
phenyl
carboxy
Prior art date
Application number
IL12246496A
Other languages
English (en)
Other versions
IL122464A0 (en
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26307176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL122464(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9511507.7A external-priority patent/GB9511507D0/en
Priority claimed from GBGB9519666.3A external-priority patent/GB9519666D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of IL122464A0 publication Critical patent/IL122464A0/xx
Publication of IL122464A publication Critical patent/IL122464A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IL12246496A 1995-06-07 1996-06-03 נגזרות של n-פיראזין- פירידינסולפונאמיד, תהליך להכנתן ותערובות רוקחיות המכילות אותן IL122464A (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9511507.7A GB9511507D0 (en) 1995-06-07 1995-06-07 Heterocyclic compounds
GBGB9519666.3A GB9519666D0 (en) 1995-09-27 1995-09-27 Heterocyclic derivatives
PCT/GB1996/001295 WO1996040681A1 (en) 1995-06-07 1996-06-03 N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists

Publications (2)

Publication Number Publication Date
IL122464A0 IL122464A0 (en) 1998-09-15
IL122464A true IL122464A (he) 2002-05-23

Family

ID=26307176

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12246496A IL122464A (he) 1995-06-07 1996-06-03 נגזרות של n-פיראזין- פירידינסולפונאמיד, תהליך להכנתן ותערובות רוקחיות המכילות אותן

Country Status (32)

Country Link
US (3) US5866568A (he)
EP (1) EP0832082B1 (he)
JP (1) JP3193058B2 (he)
KR (1) KR100451523B1 (he)
CN (1) CN1097051C (he)
AR (1) AR003132A1 (he)
AT (1) ATE209200T1 (he)
AU (1) AU715041B2 (he)
BR (1) BR9608611A (he)
CA (1) CA2219742C (he)
CZ (1) CZ289387B6 (he)
DE (1) DE69617236T2 (he)
DK (1) DK0832082T3 (he)
EG (1) EG25227A (he)
ES (1) ES2168487T3 (he)
GE (1) GEP20053470B (he)
HK (1) HK1005801A1 (he)
HR (1) HRP960272B1 (he)
HU (1) HUP9802300A3 (he)
IL (1) IL122464A (he)
MX (1) MX9709521A (he)
MY (1) MY114926A (he)
NO (1) NO314503B1 (he)
NZ (1) NZ308619A (he)
PL (1) PL187897B1 (he)
PT (1) PT832082E (he)
RU (1) RU2172738C2 (he)
SK (1) SK282338B6 (he)
TR (1) TR199701502T1 (he)
TW (1) TW340845B (he)
UA (1) UA58494C2 (he)
WO (1) WO1996040681A1 (he)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
US5977117A (en) 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
AU717230B2 (en) 1996-02-20 2000-03-23 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
GB9614804D0 (en) * 1996-07-15 1996-09-04 Chiroscience Ltd Resolution process
WO1998033781A1 (en) * 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GB9704762D0 (en) 1997-03-07 1997-04-23 Zeneca Ltd Chemical process
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
NZ336898A (en) 1997-04-28 2001-10-26 Texas Biotechnology Corp Sulfonamides for treatment of endothelin-mediated disorders
CA2367916A1 (en) 1999-03-19 2000-09-28 Ambarish Singh Methods for the preparation of biphenyl isoxazole sulfonamides
US6448239B1 (en) * 1999-06-03 2002-09-10 Trustees Of Princeton University Peroxynitrite decomposition catalysts and methods of use thereof
ES2285334T3 (es) 1999-12-31 2007-11-16 Encysive Pharmaceuticals, Inc Sulfonamidas y sus derivados como moduladores de la actividad de endotelina.
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US6858592B2 (en) 2001-06-29 2005-02-22 Genzyme Corporation Aryl boronic acids for treating obesity
US7041280B2 (en) * 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
US7169805B2 (en) * 2003-05-28 2007-01-30 Nicox S.A. Captopril derivatives
GB0320806D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
GB0403744D0 (en) * 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
KR100839512B1 (ko) * 2004-07-02 2008-06-19 주식회사 코오롱 설파제를 디아조화체로 하는 산성 항균 염료 및 그를이용한 항균 섬유
CA2586479A1 (en) 2004-11-12 2006-05-18 Trustees Of Tufts College Lipase inhibitors
US20070054325A1 (en) * 2005-04-14 2007-03-08 Reglia Materials and methods for screening modulators of neural regeneration
GB0514743D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Salt
CA2633956C (en) 2005-12-13 2016-12-06 Olivia Raeber Binding proteins specific for insulin-like growth factors and uses thereof
JP2009529005A (ja) * 2006-03-03 2009-08-13 トレント・ファーマシューティカルズ・リミテッド アンジオテンシン１受容体（ａｔ１）とエンドセリンａ（ｅｔａ）受容体に対する新規な二重作用受容体拮抗薬（ｄａｒａ）
US20100022568A1 (en) * 2006-04-13 2010-01-28 Actelion Pharmaceeuticals Ltd. Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
JP5331953B2 (ja) * 2006-09-21 2013-10-30 ピラマル エンタープライジーズ リミテッド 代謝性障害の治療のための３−アミノ−ピリジン誘導体
CL2008000191A1 (es) 2007-01-25 2008-08-22 Astrazeneca Ab Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
EP2160392A2 (en) 2007-05-03 2010-03-10 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
SI2209501T1 (sl) 2007-10-12 2012-03-30 Astrazeneca Ab Sestavki zibotentana ki vsebujejo manitol in mikrokristalinično celulozo
DK2297114T3 (en) 2008-06-19 2018-07-09 Takeda Pharmaceuticals Co Heterocyclic compound and its use
PT2394999E (pt) * 2009-02-06 2014-05-02 Nippon Shinyaku Co Ltd Derivado de aminopirazina e medicamento correspondente
CN102491973A (zh) * 2011-12-15 2012-06-13 南京友杰医药科技有限公司 Zd-4054的合成方法
WO2021262998A1 (en) * 2020-06-25 2021-12-30 Wake Forest University Health Sciences Compounds for sensing reactive oxygen species and methods for using the same
PE20230778A1 (es) 2020-07-10 2023-05-09 Astrazeneca Ab Combinacion de zibotentan y dapagliflozina para el tratamiento de la enfermedad renal cronica
CN117255791A (zh) 2021-06-22 2023-12-19 亚克医药株式会社 化合物、内皮素a受体拮抗剂及医药组合物
US20240058331A1 (en) 2022-08-12 2024-02-22 Astrazeneca Ab Combination therapies for treatment of cirrhosis with portal hypertension

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0655708B2 (ja) * 1985-05-13 1994-07-27 三井東圧化学株式会社 スルホンアミド系化合物及び農業用殺菌剤
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
EP0462179A4 (en) * 1989-02-27 1992-03-18 The Du Pont Merck Pharmaceutical Company Novel sulfonamides as radiosensitizers
TW270116B (he) * 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW224462B (he) * 1992-02-24 1994-06-01 Squibb & Sons Inc
JPH07505890A (ja) * 1992-04-22 1995-06-29 ワーナー−ランバート・コンパニー エンドセリンアンタゴニスト
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
JPH07509465A (ja) * 1992-07-17 1995-10-19 スミスクライン・ビーチャム・コーポレイション エンドセリン受容体アンタゴニスト
TW287160B (he) * 1992-12-10 1996-10-01 Hoffmann La Roche
CA2121724A1 (en) * 1993-04-21 1994-10-22 Toshifumi Watanabe Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
GB9409618D0 (en) * 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
DE4426346A1 (de) * 1994-07-25 1996-02-01 Basf Ag Herbizide Pyrazinderivate
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
GB2295616A (en) * 1994-12-01 1996-06-05 Zeneca Ltd N-Diazine-benzenesulphonamide derivatives as endothelin receptor antagonists
ATE243203T1 (de) * 1995-04-04 2003-07-15 Texas Biotechnology Corp Thienyl-, furyl-, pyrrolyl- und biphenylsulfonamide und derivate zur modulation der endothelin-aktivität

Also Published As

Publication number Publication date
DE69617236D1 (de) 2002-01-03
AU5840396A (en) 1996-12-30
ATE209200T1 (de) 2001-12-15
PL324660A1 (en) 1998-06-08
US6060475A (en) 2000-05-09
HUP9802300A3 (en) 2002-02-28
US6258817B1 (en) 2001-07-10
CN1097051C (zh) 2002-12-25
SK168097A3 (en) 1998-05-06
HUP9802300A2 (hu) 1999-10-28
AU715041B2 (en) 2000-01-13
GEP20053470B (en) 2005-02-25
EP0832082B1 (en) 2001-11-21
PT832082E (pt) 2002-04-29
DK0832082T3 (da) 2002-05-21
TR199701502T1 (xx) 1998-03-21
NO314503B1 (no) 2003-03-31
CA2219742A1 (en) 1996-12-19
BR9608611A (pt) 1999-05-11
DE69617236T2 (de) 2002-07-11
CA2219742C (en) 2007-01-16
CZ388797A3 (cs) 1998-03-18
IL122464A0 (en) 1998-09-15
NZ308619A (en) 2000-01-28
CN1192739A (zh) 1998-09-09
JP3193058B2 (ja) 2001-07-30
EP0832082A1 (en) 1998-04-01
CZ289387B6 (cs) 2002-01-16
MX9709521A (es) 1998-03-31
UA58494C2 (uk) 2003-08-15
KR19990022327A (ko) 1999-03-25
HRP960272A2 (en) 1997-08-31
JPH11509175A (ja) 1999-08-17
RU2172738C2 (ru) 2001-08-27
US5866568A (en) 1999-02-02
EG25227A (en) 2011-11-17
HRP960272B1 (en) 2006-06-30
AR003132A1 (es) 1998-07-08
ES2168487T3 (es) 2002-06-16
HK1005801A1 (en) 1999-01-29
NO975700D0 (no) 1997-12-05
SK282338B6 (sk) 2002-01-07
PL187897B1 (pl) 2004-10-29
MY114926A (en) 2003-02-28
WO1996040681A1 (en) 1996-12-19
TW340845B (en) 1998-09-21
NO975700L (no) 1997-12-05
KR100451523B1 (ko) 2004-12-03

Similar Documents

Publication Publication Date Title
US6060475A (en) Substituted pyrazin-2-yl-sulphonamide-(3-pyridyl) compounds and uses thereof
US11267800B2 (en) Cyclohexyl acid triazole azines as LPA antagonists
US5668137A (en) N-heterocyclic sulfonamides having endothelin receptor activity
US11447475B2 (en) Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
US8846933B2 (en) N-link hydroxamic acid derivatives useful as antibacterial agents
GB2474748A (en) 5-Biphenylisoxazole derivatives as lysophosphatidic acid receptor antagonists
US20080032992A1 (en) New Pyridine Analogues V
KR20200100712A (ko) Lpa 길항제로서의 피라졸 n-연결된 카르바모일 시클로헥실 산
AU2013255437A1 (en) Substituted pyridine compounds as CRAC modulators
US20080045494A1 (en) Pyridine Analogues VI
US20090312368A1 (en) Pyridine Analogues IV
US20220235027A1 (en) Cyclobutyl carboxylic acids as lpa antagonists
EP3083587A1 (en) Oximino derivatives for the treatment of dyslipidemia

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees